Company profile: CytoSorbents
1.1 - Company Overview
Company description
- Provider of blood purification therapies and devices for treating life-threatening conditions, including CytoSorb to reduce excessive cytokines during ICU care and cardiac surgery; investigational DrugSorb-ATR to remove antithrombotic agents during cardiothoracic surgery; VetResQ for critically ill animals; ECOS-300CY for ex vivo organ perfusion; development-stage HemoDefend-RBC and HemoDefend-BGA for safer transfusions.
Products and services
- CytoSorb: An ICU-grade blood purification therapy that reduces excessive cytokines and other inflammatory mediators from blood in the ICU and during cardiac surgery to treat life-threatening illnesses
- HemoDefend-RBC: A development-stage blood purification technology intended to reduce transfusion reactions and improve the safety and quality of transfused blood for the blood transfusion industry
- DrugSorb-ATR: An investigational blood purification technology that removes antithrombotic agents, including ticagrelor, during cardiothoracic surgery to reduce perioperative bleeding
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CytoSorbents
Algonomics
HQ: Belgium
Website
- Description: Provider of structural bioinformatics services to develop rationally designed therapeutics in immunotherapy, leveraging a proprietary platform for structure-based protein and peptide design. Belgium-based biotech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algonomics company profile →
Unchained Labs
HQ: United States
Website
- Description: Provider of life science biologics tools, including platforms for protein stability, quantification, sizing, and characterization. Products include Uncle for biologics stability screening; Stunner for quantification and sizing of LNPs, proteins and aggregates; Lunatic for high-throughput protein/nucleic acid quantification; Leprechaun for lentivirus/exosome characterization; Sunshine for LNP process development; Honeybun for rapid viscosity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Unchained Labs company profile →
LumaCyte
HQ: United States
Website
- Description: Provider of label-free single-cell analysis solutions that accelerate medical discoveries, including Radiance, an instrument measuring cellular response using optical and fluidic forces; Laser Force Cytology technology; and software suites Illuminate for control/data analysis and ReportR for automated cloud reporting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LumaCyte company profile →
CN Bio
HQ: United Kingdom
Website
- Description: Provider of human organ-on-a-chip platforms and services for drug discovery and disease research, including PhysioMimix OOC single- and multi-organ systems, PhysioMimix HT for higher-throughput R&D, contract research services, and liver and lung assays covering NASH, HBV, and COVID-19 for long-term culture, infection modeling, drug efficacy, safety testing, and immune response studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CN Bio company profile →
Ossiform
HQ: Denmark
Website
- Description: Provider of 3D bone printing solutions, including P3D Bone - bio-integrative, resorbable implants made from beta-tricalcium phosphate tailored to biomechanical needs; P3D Scaffolds - 3D printed bioceramic structures for cell culture, disease modeling, and drug screening; and Bone Printing Technology using beta-tricalcium phosphate to create implants with customizable porosity and mechanical properties.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ossiform company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CytoSorbents
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CytoSorbents
2.2 - Growth funds investing in similar companies to CytoSorbents
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CytoSorbents
4.2 - Public trading comparable groups for CytoSorbents
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →